# BiPar Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bipar-sciences

- Industry: Pharmaceuticals
- Headquarters: South San Francisco, US
- Website: www.biparsciences.com
- Total disclosed funding: $45M
- Latest round: Series C (Dec 22, 2008)
- Investors on record: 6

## About

BiPar is a clinical-stage drug development company pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients.

## Funding rounds

- Series C, Dec 22, 2008, $15M — Domain Associates, Canaan Partners, PolyTechnos Venture-Partners, Asset Management Ventures, Vulcan, Quantum Technology Partners
- Series B, Feb 26, 2007, $18M — Domain Associates, Canaan Partners, PolyTechnos Venture-Partners, Asset Management Ventures, Vulcan, Quantum Technology Partners
- Series A, Dec 1, 2004, $13M — Canaan Partners, PolyTechnos Venture-Partners, Asset Management Ventures, Vulcan, Quantum Technology Partners

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B, Series C
- PolyTechnos Venture-Partners (https://capitalatlas.ai/funds/polytechnos-venture-partners) — Series A, Series B, Series C
- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series A, Series B, Series C
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series A, Series B, Series C
- Quantum Technology Partners (https://capitalatlas.ai/funds/quantum-technology-partners) — Series A, Series B, Series C
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B, Series C